Disseminated fungal infection in a patient receiving zanubrutinib
Authors:
Open Access
- 13 June 2023
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 11 (6) , e7564
Abstract
Key Clinical Message: We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.Keywords
All Related Versions
Funding Information
- University of Iowa
This publication has 7 references indexed in Scilit:
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialJournal of Clinical Oncology, 2023
- Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular diseaseCell Death Discovery, 2022
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse EffectsFrontiers in Cell and Developmental Biology, 2021
- Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infectionsBlood Reviews, 2020
- Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLBlood, 2019
- Incidence of opportunistic infections during ibrutinib treatment for B-cell malignanciesLeukemia, 2019
- Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling PathwaysClinical Infectious Diseases, 2017